Filing Details

Accession Number:
0001562180-24-003829
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-03 18:30:08
Reporting Period:
2024-05-01
Accepted Time:
2024-05-03 18:30:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1710072 Edgewise Therapeutics Inc. EWTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1644467 Michael R Carruthers C/O Edgewise Therapeutics, Inc.
1715 38Th Street
Boulder CO 80301
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-01 5,208 $0.00 37,387 No 4 M Direct
Common Stock Disposition 2024-05-02 2,157 $18.91 35,230 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-05-01 5,208 $0.00 5,208 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,209 2032-05-01 No 4 M Direct
Footnotes
  1. Includes 2,898 shares purchased on May 15, 2023 and 257 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
  2. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
  3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.